TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02345304
Drug: BI 1181181
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345304
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02345304
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01034540
Drug: POM3
Normalized name: Potassium Orotate Magnesium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 g/day
Study: NCT01193881
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03663881
Drug: P2Et extract
Normalized name: Turmeric Extract
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
Study: NCT03344094
Drug: ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FDA-approved MS drugs
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 2.5 mg, once daily, 12 weeks
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 5 mg, once daily, 12 weeks
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 10 mg, once daily, 12 weeks
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 20 mg, once daily, 12 weeks
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 40 mg, once daily, 12 weeks
Study: NCT00950599
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 100 mg, once daily, 6 weeks
Study: NCT03808818
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given NRT patch or lozenge (or both)
Study: NCT03858634
Drug: KPL-716
Normalized name: Immunoglobulin g (234-proline,303-glutamine), anti-(human oncostatin m receptor subunit .beta.) (human monoclonal kpl-716 .gamma.-chain), disulfide with human monoclonal kpl-716 .lambda.-chain, dimer
DrugBank: Vixarelimab (DB16350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
Study: NCT03596918
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04481009
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administrated each 21-day cycle.
Study: NCT00243464
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00393809
Drug: DTA-H19
Normalized name: dT-A-H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02465385
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
Study: NCT01542268
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
Study: NCT01542268
Drug: pentoxifylline placebo
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
Study: NCT01854645
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
Study: NCT01854645
Drug: FF MDI
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF MDI administered as two puffs BID
Study: NCT01854645
Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
Normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Study: NCT05354076
Drug: doxorubicin hydrochloride liposome injection
Normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
Study: NCT02632565
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632565
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02095119
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
Study: NCT02095119
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is \>/= 60. The administration form will be intravenously.
Study: NCT02095119
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation \< 60). The administration form will be intravenously.
Study: NCT00947518
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
Study: NCT04130919
Drug: Tilpisertib
Normalized name: Tilpisertib
DrugBank: Tilpisertib (DB18798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00458718
Drug: rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02481479
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
Study: NCT02481479
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
Study: NCT02481479
Drug: saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
Study: NCT00700284
Drug: TMC120 (dapivirine) vaginal ring
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal ring containing 120 mg TMC120 (dapivirine)
Study: NCT03707184
Drug: Fluciclovine F18
Normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02729194
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03826485
Drug: Pranlukast hydrate
Normalized name: Chloral Hydrate
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast hydrate 225mg/2.25g
Study: NCT01453920
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Ranibizumab 0.05cc (10mg/ml)
Study: NCT01228396
Drug: Hyperimmune caprine serum against HIV lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
Study: NCT02647554
Drug: ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ulinastatin 400,000 IU every 8 hours for 10 days
Study: NCT01947556
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
Study: NCT00125931
Drug: Talwin Nx
Normalized name: Talwin NX
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talwin NX 50mg po twice
Study: NCT02777931
Drug: NFC-1
Normalized name: Nivolumab and Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NFC-1 is supplied as size 2 hard gelatin capsules.
Study: NCT01430104
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously during the Treatment Period
Study: NCT01430104
Drug: Aspara-CA 600 mg
Normalized name: fenoprofen
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally throughout the study
Study: NCT00091182
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04304625
Drug: Tranexamic Acid / Sodium chloride
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
Study: NCT01217203
Drug: IPH2101 combined to lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)
Study: NCT02189395
Drug: NPH and regular insulin
Normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02503722
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02503722
Drug: Sapanisertib
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03888716
Drug: KL1333
Normalized name: KL1333
DrugBank: KL1333 (DB17622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 and 100 mg KL1333 encapsulated tablets
Study: NCT00662714
Drug: Repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral; initial dose: 3x 0.5mg/d; 2 years
Study: NCT04442022
Drug: Selinexor (combination therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study: NCT04442022
Drug: Selinexor (combination therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study: NCT04442022
Drug: Selinexor (combination therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study: NCT04442022
Drug: Placebo matching for Selinexor (combination therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study: NCT04442022
Drug: Rituximab (combination therapy)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
Study: NCT04442022
Drug: Rituximab (combination therapy)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
Study: NCT04442022
Drug: Gemcitabine (combination therapy)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
Study: NCT04442022
Drug: Dexamethasone (combination therapy)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Study: NCT04442022
Drug: Cisplatin (combination therapy)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
Study: NCT04442022
Drug: Selinexor (continuous therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
Study: NCT04442022
Drug: Placebo matching for Selinexor (continuous therapy)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
Study: NCT03125057
Drug: Hemoporfin PDT
Normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
Study: NCT00457665
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457665
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03559010
Drug: Norgestrel 0.075 mg tablets
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet.
Study: NCT03150173
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: all participants will receive buprenorphine
Study: NCT00690768
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
Study: NCT01624805
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01624805
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT04643470
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01571635
Drug: SOTATERCEPT (ACE-011)
DrugBank: Sotatercept (DB12118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
Study: NCT03792984
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
Study: NCT02392845
Drug: Combination of Docetaxel (DTX) and Epirubicin (EPI)
Normalized name: combinations of levothyroxine and liothyronine
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
Study: NCT01617148
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
Study: NCT02003222
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, or SC
Study: NCT02003222
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02003222
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02003222
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02003222
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02003222
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT02003222
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02003222
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02003222
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03459833
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
Study: NCT02122471
Drug: Plecanatide
Normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04079686
Drug: Cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
Study: NCT02992522
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02992522
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04505904
Drug: Syntocinon
Normalized name: Syntocinon
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic oxytocin spray, 24 IU per spray.
Study: NCT00613197
Drug: Epanova
Normalized name: Epanova
DrugBank: Omega-3-carboxylic acids (DB09568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4g/day in divided doses
Study: NCT02629809
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02629809
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00124449
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g